The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.
The current definition of complete response in multiple myeloma includes a requirement for a bone marrow (BM) examination showing less than 5% plasma cells in addition to negative serum and urine immunofixation. There have been suggestions to eliminate the need for BM examinations when defining complete response. We evaluated 92 patients with multiple myeloma who achieved negative immunofixation in the serum and urine after therapy and found that 14% had BM plasma cells more than or equal to 5%. Adding a requirement for normalization of the serum-free light chain ratio to negative immunofixation studies did not negate the need for BM studies; 10% with a normal serum-free light chain ratio had BM plasma cells more than or equal to 5%. We also found that, on achieving immunofixation-negative status, patients with less than 5% plasma cells in the BM had improved overall survival compared with those with 5% or more BM plasma cells (6.2 years vs 2.3 years, respectively; P = .01).
Chee
Cheng E
CE
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Kumar
Shaji
S
Larson
Dirk R
DR
Kyle
Robert A
RA
Dispenzieri
Angela
A
Gertz
Morie A
MA
Colby
Colin L
CL
Rajkumar
S Vincent
SV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology*; D001856:Bone Marrow Examination; D002452:Cell Count; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000652:urine; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010950:Plasma Cells / Q000473:pathology; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis
D007136:Immunoglobulins